Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Brief Summary: This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with sorafenib tosylate is more effective than carboplatin and paclitaxel in treating melanoma.


Options:
A: Arm Label: Arm I (paclitaxel, carboplatin, sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm II (carboplatin, paclitaxel, placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Other: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate)
B: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
C: Arm Label: Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ) | Arm Label: Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ), Drug: Pegylated Interferon Alpha-2b (PGI) | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Temozolomide (TMZ), Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI) | Intervention Type: DRUG; Name: Pegylated Interferon Alpha-2b (PGI); Assigned to Arm(s): Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)
D: Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Corticosteroid: Betamethasone, Drug: Corticosteroid: Dexamethasone, Drug: Corticosteroid: Fludrocortisone, Drug: Corticosteroid: Hydrocortisone, Drug: Corticosteroid: Meprednisone, Drug: Corticosteroid: Methylprednisolone, Drug: Corticosteroid: Prednisolone, Drug: Corticosteroid: Prednisone, Drug: Corticosteroid: Triamcinolone | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients, Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients | Intervention Type: DRUG; Name: Corticosteroid: Betamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Dexamethasone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Fludrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Hydrocortisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Meprednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Methylprednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Prednisone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients | Intervention Type: DRUG; Name: Corticosteroid: Triamcinolone; Assigned to Arm(s): Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients

Answer: A